Table 1 Laboratory data (Patient 1, 2)
| Pt 1 | Pt 2 | Reference value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Admission | Onset |
Nadir During First two weeks | Discharge | Admissiona | Onset |
Nadir During First two weeks | Discharge | |||
| Biochemistry | BUN (mg/dL) | 40.9 | 13.3 | 12.2 | 19.8 | 23.3 | 23.3 | 17.7 | 9.6 | 8–20 |
| Cre (mg/dL) | 0.73 | 0.32 | 0.30 | 0.42 | 0.55 | 0.55 | 0.55 | 1.29 | 0.46–0.79 | |
| BUN/Cre | 56.03 | 41.56 | NA | 47.14 | 42.36 | 42.36 | NA | 7.44 | ||
| Glucose (mg/dL) | 177 | 86 | 80 | 103 | 99 | 99 | 89 | 90 | 73–109 | |
| Na (mmol/L) | 135 | 142 | 135 | 139 | 137 | 137 | 137 | 141 | 138–145 | |
| Cl (mmol/L) | 88 | 112 | 88 | 109 | 96 | 96 | 96 | 105 | 101–108 | |
| K (mmol/L) | 2.8 | 4.5 | 2.8 | 4.3 | 3.4 | 3.4 | 3.4 | 3.4 | 3.6–4.8 | |
| Ca (mg/dL) | 7.7 | 7.7 | 7.7 | 8.8 | 8.0 | 8.0 | 7.9 | 8.3 | 8.8–10.2 | |
| Mg (mg/dL) | 2.8 | 1.5 | 1.4 | 1.8 | 1.8 | 1.8 | 1.8 | 3.0 | 1.8–2.4 | |
| P (mg/dL) | 3.6 | 2.4 | 2.2 | 4 | 4.5 | 4.5 | 4.5 | 5.1 | 2.4–4.6 | |
| AST | 244 | 52 | 26 | 23 | 46 | 46 | 37 | 15 | ||
| ALT | 135 | 87 | 51 | 40 | 88 | 88 | 19 | 12 | ||
| CRP | < 0.01 | < 0.01 | < 0.01 | < 0.01 | < 0.10 | < 0.10 | < 0.10 | < 0.10 | ||
| TC (mg/dL) | 195 | 155 | 155 | 191 | 212 | 212 | 212 | 295 | 142–248 | |
| TG (mg/dL) | 24 | 58 | 24 | 47 | 71 | 71 | 71 | 151 | 30–117 | |
| HDL-C (mg/dL) | 119 | 65 | 65 | 89 | 82 | 82 | 82 | 90 | 48–103 | |
| LDL-C (mg/dL) | 77 | 81 | 77 | 91 | 122 | 122 | 122 | 181 | 65–163 | |
| FT3 (pg/mL) | < 1.5 | 2.24 | < 1.5 | NA | 2.05 | 2.05 | 2.05 | 1.79 | 1.88–3.18 | |
| FT4 (ng/dL) | 1.31 | 0.74 | 0.74 | NA | 0.72 | 0.72 | 0.72 | 0.82 | 0.7–1.4 | |
| TSH (μIU/mL) | 2.04 | 1.18 | 1.18 | NA | 1.24 | 1.24 | 1.24 | 0.28 | 0.35–4.94 | |
| Hb-A1c (%) | 5.8 | 5.8 | 5.8 | NA | 6.2 | 6.2 | 6.2 | 4.9 | 4.9–6.0 | |
| BNP (pg/mL) | 41.9 | 50.4 | 41.9 | NA | NA | NA | NA | NA | 0–18.41 | |
| Blood count | WBC (/μL) | 4200 | 2500 | 2300 | 4600 | 10,500 | 10,500 | 4200 | 8700 | 3300–8600 |
| RBC (X10^4/μL) | 392 | 260 | 233 | 333 | 286 | 286 | 262 | 372 | 386–492 | |
| Hb (g/dL) | 13.3 | 9.1 | 8.1 | 11.8 | 7.5 | 7.5 | 6.9 | 7.8 | 11.6–14.8 | |
| Hct (%) | 38.3 | 27.5 | 25.4 | 37.4 | 24.3 | 24.3 | 23.0 | 27.5 | 35.1–44.4 | |
| Plt (X10^4/μL) | 15.5 | 14.6 | 9.5 | 21.3 | 54.3 | 54.3 | 49.1 | 54.5 | ||
| Coagulation profile | PT-INR | 1.49 | 1.14 | 1.14 | NA | 0.99 | 0.99 | 0.93 | NA | 0.8–1.2 |
| APTT (sec) | 29.3 | 24.6 | 24.6 | NA | 23.3 | 23.3 | 18 | 37.7 | 23.5–31.5 | |
| D-dimer (μg/mL) | < 0.25 | 1.2 | < 0.25 | NA | 1.7 | 1.7 | 1.2 | 0.6 | 0–1 | |
| TAT III (ng/L) | NA | 26.9 | 26.9 | 3.6 | 3.6 | 3.6 | 3.6 | NA | 0–3 | |
| Protein C activity (%) | NA | 57 | 57 | NA | 97 | 97 | 97 | NA | 64–146 | |
| Protein S (%) | NA | 84 | 84 | NA | 120 | 120 | 120 | NA | 60–150 | |
| PF4 (ng/mL) | NA | 33 | 33 | 70 | 24 | 24 | 24 | NA | 0–20 | |
| βTG (ng/mL) | NA | 104 | 104 | 129 | 105 | 105 | 105 | NA | 0–50 | |
| Autoimmune antibodiesb | ANA | 20 | < 20 | < 20 | ||||||
| PR3-ANCA (U/mL) | < 1.0 | < 1.0 | 0–3.5 | |||||||
| MPO-ANCA (U/mL) | < 1.0 | < 1.0 | 0–3.5 | |||||||
| Anti-cardiolipin antibody (U/mL) | < 10 | 8 | 0–10 | |||||||
| Imaging findingsb | Ultrasound (carotid artery) | no atherosclerosis | no atherosclerosis | |||||||
| Ultrasound (lower extremity veins) | no embolism | no embolism | ||||||||
| Whole-body CT | no evidence of malignancy | no evidence of malignancy | ||||||||
| Holter ECG | no evidence of Af | no evidence of Af | ||||||||
| Echocardiography |
EF 70% Wall motion normal No embolism |
EF 70% Wall motion normal No embolism | ||||||||
| CAVI/ABIb | CAVI (R/L) | 7.8/7.7 | 7.1/6.9 | |||||||
| ABI (R/L) | 0.77/0.83 | 1.04/1.05 | ||||||||
| CSFb | CSF cell count (/μL) | NA | 1 | 0–5 | ||||||
| CSF protein (mg/dL) | NA | 24 | 15–45 | |||||||
| CSF IgG-index | NA | 0.19 | 0–0.7 | |||||||
| CSF MBP | NA | negative | negative | |||||||
| CSF OCB | NA | negative | negative | |||||||